Welcome to our dedicated page for Astronics SEC filings (Ticker: ATRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astronics Corporation (NASDAQ: ATRO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered tools to help interpret them. As a supplier of advanced technologies and products to aerospace, defense and other mission-critical industries, Astronics uses its filings to report on segment performance, capital structure, risk factors and material agreements.
Investors can review current reports on Form 8-K that describe material events such as the entry into a new cash flow-based revolving credit facility, the termination of a prior asset-based credit agreement, and the issuance of 0% Convertible Senior Notes due 2031 paired with capped call transactions. These filings outline key terms, covenants, leverage and interest coverage ratios, and the use of proceeds for refinancing existing convertible notes and supporting general corporate purposes.
In addition to 8-Ks, Astronics’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) provide detail on the Aerospace and Test Systems segments, including how the company categorizes its markets, discloses research and development expense, and discusses bookings and backlog. Proxy materials and other filings offer further insight into governance and capital structure.
Stock Titan enhances access to these documents with AI-powered summaries that explain complex sections, highlight important terms in credit agreements and indentures, and clarify the implications of convertible note offerings and covenant packages. Users can also track insider transaction reports on Form 4 and other ownership-related filings to see how executives and significant holders are trading Astronics stock. Together, these tools help readers navigate Astronics’ regulatory record without manually parsing every page of each filing.
Astronics Corporation filed a current report to note that it issued a news release with preliminary unaudited revenue and bookings for the fourth quarter of 2025, preliminary unaudited revenue for full year 2025, and initial revenue guidance for 2026. The detailed figures and outlook are contained in the attached press release, listed as Exhibit 99.1, which accompanies this report.
Astronics Corp insider Peter J. Gundermann, the company’s President, CEO and a director, reported a new grant of 29,750 stock options on December 4, 2025. The options have an exercise price of $51.72 per share, become exercisable on December 4, 2026, and expire on December 4, 2035, and relate to $.01 par value common stock.
After the reported transaction, he directly owned 83,906.608 shares of $.01 par value common stock and 747,911 shares of $.01 par value Class B stock. The filing also lists multiple existing option grants and restricted stock units, each RSU representing the right to receive one share of common stock at settlement. Several RSU awards for 9,206, 26,450 and 25,250 shares may vest in 2026, 2027 and 2028 based on Astronics’ average annual adjusted EBITDA over the periods January 1, 2023–December 31, 2025, January 1, 2024–December 31, 2026, and January 1, 2025–December 31, 2027, with vesting ranges between 75% and 115% or between 50% and 150% of target depending on the grant.
Astronics Corp executive James Mulato, President of Astronics Test Systems, reported a stock transaction and updated his equity holdings. On 12/01/2025, he sold 9,734 shares of $.01 par value common stock at $53.24 per share. After this sale, he directly holds 27,077.822 shares of common stock and 2,453 shares of Class B stock.
He also reports a broad set of stock options on Astronics common and Class B stock, with exercise prices ranging from $9.74 to $35.61 and expiration dates from 2026 through 2033. In addition, he holds performance-based restricted stock units (RSUs): 18,550 units tied to average annual adjusted EBITDA for 2024–2026 that may vest between 50% and 150% of target on February 22, 2027; 11,500 units tied to EBITDA for 2023–2025 that may vest between 75% and 115% on February 23, 2026; and 17,700 units tied to EBITDA for 2025–2027 that may vest between 50% and 150% on February 27, 2028, all based on actual performance.
Astronics Corp (ATRO) reported insider equity activity by its President and CEO, who is also a director. On 11/20/2025, he exercised stock options for 13,700 shares of $.01 par value common stock and 4,418 shares of $.01 par value Class B stock at an exercise price of $27.72 per share. To cover withholding taxes from the option exercise, 11,707 common shares were withheld at a price of $49.35 per share. Following these transactions, he beneficially owned 83,906.608 shares of common stock and 747,911 shares of Class B stock directly. The filing also lists multiple remaining stock option grants and restricted stock units that vest over future years based on Astronics’ average annual adjusted EBITDA performance metrics, with potential vesting between 50% and 150% of target. This Form 4 clarifies that these transactions are being reported on an original filing rather than an amendment.
Astronics Corp. (ATRO) President and CEO Peter J. Gundermann reported multiple equity transactions dated 11/20/2025. He exercised stock options to acquire 13,700 shares of $.01 par value common stock and 4,418 shares of $.01 par value Class B stock at an exercise price of $27.72 per share. To cover withholding taxes tied to the option exercise, 11,707 common shares were withheld at a price of $49.35 per share. Following these transactions, he directly owned 83,906.608 common shares and 747,911 Class B shares.
The filing also lists outstanding equity awards. These include multiple stock option grants with exercise prices ranging from $9.74 to $35.61 per share and expirations between 12/03/2025 and 12/07/2033, as well as several restricted stock unit awards tied to Astronics’ average annual adjusted EBITDA performance for periods running from 2023–2027, with potential vesting ranges between 50% and 150% of target on future dates.
Astronics Corp (ATRO) Executive VP & President–Aerospace Mark Peabody reported exercising stock options and acquiring company shares. On 11/19/2025, he exercised options to acquire 4,500 shares of $.01 par value common stock at $27.72 per share and 1,451 shares of $.01 par value Class B stock at $27.72 per share. Following these transactions, he beneficially owned 55,324.73 common shares and 185,445 Class B shares directly.
The filing also lists multiple option grants and restricted stock units. Several RSU awards vest based on Astronics’ average annual adjusted EBITDA over multi‑year periods ending December 31, 2025, December 31, 2026, and December 31, 2027, with between 50% and 150% (or 75% to 115% for one grant) of target units eligible to vest in February 2026, February 2027, and February 2028 based on actual performance.
Astronics Corp (ATRO) officer and Principal Accounting Officer Nancy L. Hedges reported multiple equity transactions. On 11/17/2025, she exercised stock options for a total of 3,600 shares of common and Class B stock at exercise prices of $27.72 and $31.76. Some of the resulting common shares were withheld by Astronics to cover tax obligations at a price of $52.15.
After these transactions, she continued to hold Astronics common and Class B shares directly, as well as several blocks of restricted stock units (RSUs). These include 17,700, 5,024, and 5,050 RSUs, each representing the right to receive one share of common stock at settlement. Two RSU awards vest between 50% and 150% of a target amount based on Astronics’ average annual adjusted EBITDA over performance periods running through December 31, 2026 and December 31, 2027, with potential vesting on February 22, 2027 and February 27, 2028. Another RSU grant is scheduled to vest February 23, 2026.
Astronics Corporation reported Q3 2025 results with sales of $211.4 million, up from $203.7 million a year ago. For the nine months, sales reached $622.1 million, and income from operations rose to $41.0 million, helping narrow the year-to-date net loss to $0.3 million. Operating cash flow improved to $47.2 million, reflecting better working capital trends.
The company refinanced and extended its capital structure: it issued $225.0 million zero-coupon 2031 convertible notes, partially repurchased $132.0 million of 2030 notes (recording a $32.6 million inducement loss), entered capped calls for $26.9 million, and ended the quarter with $85.0 million drawn on its ABL. Backlog was $646.7 million, with $479.2 million expected over the next twelve months.
Subsequent to quarter-end, Astronics acquired Bühler Motor Aviation for $18.0 million and replaced its ABL with a $300 million secured revolver maturing in 2030. During 2025, the company paid $21.6 million related to a UK legal matter. As of October 30, 2025, 35,629,121 shares were outstanding.
Astronics Corporation furnished an 8-K to announce its third quarter 2025 financial results. The company reported that a news release detailing the results is attached as Exhibit 99.1.
The information in this report, including Exhibit 99.1, is provided under Item 2.02 and is expressly stated as furnished, not filed, under the Exchange Act and Securities Act. The filing also includes Exhibit 104, the cover page interactive data file embedded within Inline XBRL.
Astronics Corp (ATRO) disclosed an insider equity transaction on a Form 4. Officer James Mulato (President, Astronics Test Systems) exercised stock options on 10/22/2025, acquiring 4,300 shares of $.01 par value Common Stock and 1,387 shares of $.01 par value Class B Stock at an exercise price of $27.72 per share.
Following these transactions, Mulato beneficially owned 36,811.822 shares of Common Stock and 2,453 shares of Class B Stock, held directly. The filing shows multiple remaining option grants with various exercise prices and expirations, as well as performance-based RSUs. Footnotes state that RSUs vest based on average annual adjusted EBITDA over specified multi-year periods, with vesting on stated dates tied to performance outcomes.